Overview

The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma

Status:
Recruiting

Trial end date:
2023-03-30

Target enrollment:

Participant gender:

Summary

This is a phase II trial to explore the feasibility of PD-1 immune check point inhibitor, sintilimab, in combination of stand of care chemotherapy in first-line treatment of selected soft tissue sarcoma.

Phase:

Phase 2

Details

Lead Sponsor:

Fudan University

Collaborators:

Shanghai Zhongshan Hospital
Tongji Hospital
Xijing Hospital
Zhejiang Cancer Hospital

Treatments:

Doxorubicin
Ifosfamide
Liposomal doxorubicin